Anzeige
Meldung des Tages: $95 Silber explodiert – Prince Silver vor dem nächsten Durchbruch!!
Werbung
Attraktive Knock-Outs auf Amgen Inc
Typ Hebel Bid / Ask WKN
Call
4,5 6,58 € / 6,61 €
SW0SD9
Typ Hebel Bid / Ask WKN
Put
3,6 8,13 € / 8,16 €
SW1F7M
Den Basisprospekt sowie endgültige Bedingungen und Basisinformationsblätter erhalten Sie bei Klick auf das Dokument-Icon. Beachten Sie auch die weiteren Hinweise zu dieser Werbung. Der Emittent ist berechtigt, Wertpapiere mit open end-Laufzeit zu kündigen.
Alle Knock-Outs auf Amgen Inc

Amgen Aktie News

Aktie
WKN:  867900 ISIN:  US0311621009 US-Symbol:  AMGN Branche:  Pharmazeutika Land:  USA
347,07 $
+3,50 $
+1,02%
295,49 € 22.01.26
Depot/Watchlist
Marktkapitalisierung *
152,02 Mrd. €
Streubesitz
15,92%
KGV
15,52
Dividende
2,38 $
Dividendenrendite
0,68%
neu: Nachhaltigkeits-Score
40 %
Index-Zuordnung
Dow Jones Industrial Average
Weiter aufwärts? Long handeln - Jetzt mit Hebel 5,04: VH4VXJ
Werbung

Amgen News

08.11.25 - PR Newswire
AMGEN'S REPATHA® CUTS RISK OF FIRST MAJOR ADVERSE CARDIOVASCULAR EVENTS BY 25% IN LANDMARK PHASE 3 VESALIUS-CV TRIAL
AMGEN'S REPATHA® CUTS RISK OF FIRST MAJOR ADVERSE CARDIOVASCULAR EVENTS BY 25% IN LANDMARK PHASE 3 VESALIUS-​CV TRIAL PR Newswire
04.11.25 - PR Newswire
AMGEN REPORTS THIRD QUARTER 2025 FINANCIAL RESULTS
AMGEN REPORTS THIRD QUARTER 2025 FINANCIAL RESULTS PR Newswire
31.10.25 - PR Newswire
AMGEN ANNOUNCES 2025 FOURTH QUARTER DIVIDEND
AMGEN ANNOUNCES 2025 FOURTH QUARTER DIVIDEND PR Newswire
31.10.25 - PR Newswire
AMGEN'S LANDMARK PHASE 3 REPATHA DATA TO BE PRESENTED AS LATE BREAKER AT THE AMERICAN HEART ASSOCIATION SCIENTIFIC SESSIONS 2025
AMGEN'S LANDMARK PHASE 3 REPATHA DATA TO BE PRESENTED AS LATE BREAKER AT THE AMERICAN HEART ASSOCIATION SCIENTIFIC SESSIONS 2025 PR Newswire
29.10.25 - PR Newswire
AMGEN ANNOUNCES WEBCAST OF 2025 THIRD QUARTER FINANCIAL RESULTS
AMGEN ANNOUNCES WEBCAST OF 2025 THIRD QUARTER FINANCIAL RESULTS PR Newswire
17.10.25 - PR Newswire
FDA APPROVES TEZSPIRE® FOR CHRONIC RHINOSINUSITIS WITH NASAL POLYPS
FDA APPROVES TEZSPIRE® FOR CHRONIC RHINOSINUSITIS WITH NASAL POLYPS PR Newswire
13.10.25 - wallstreetONLINE Redaktion
Angst vor Verlusten?: Diese Aktie bringt Sie sicher und dividendenstark durch die nächste Korrektur!
Die Volatilität am Aktienmarkt ist "dank" US-​Präsident Donald Trump zurück. Die Aktie von US-​Pharmakonzern Pfizer bietet Sicherheit und stabile Cashflows. Willkommen zum ...
06.10.25 - PR Newswire
/C O R R E C T I O N -- Amgen/
/C O R R E C T I O N -- Amgen/ PR Newswire
02.10.25 - PR Newswire
LANDMARK PHASE 3 TRIAL (VESALIUS-CV) MEETS PRIMARY ENDPOINTS IN A CARDIOVASCULAR PRIMARY PREVENTION STUDY OF 12,000 PATIENTS
LANDMARK PHASE 3 TRIAL (VESALIUS-​CV) MEETS PRIMARY ENDPOINTS IN A CARDIOVASCULAR PRIMARY PREVENTION STUDY OF 12,000 PATIENTS PR Newswire
26.09.25 - PR Newswire
AMGEN ANNOUNCES $650M EXPANSION OF U.S. MANUFACTURING, CREATING HUNDREDS OF NEW JOBS
AMGEN ANNOUNCES $650M EXPANSION OF U.S. MANUFACTURING, CREATING HUNDREDS OF NEW JOBS PR Newswire
08.09.25 - PR Newswire
AMGEN AND KYOWA KIRIN ANNOUNCE TOP-LINE RESULTS FROM ROCATINLIMAB PHASE 3 ASCEND LONG-TERM EXTENSION STUDY IN ADULTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS
AMGEN AND KYOWA KIRIN ANNOUNCE TOP-LINE RESULTS FROM ROCATINLIMAB PHASE 3 ASCEND LONG-TERM EXTENSION STUDY IN ADULTS WITH MODERATE TO ...
04.09.25 - PR Newswire
AMGEN TO PRESENT AT THE MORGAN STANLEY 23RD ANNUAL GLOBAL HEALTHCARE CONFERENCE
AMGEN TO PRESENT AT THE MORGAN STANLEY 23RD ANNUAL GLOBAL HEALTHCARE CONFERENCE PR Newswire
02.09.25 - PR Newswire
AMGEN INVESTING MORE THAN HALF A BILLION DOLLARS IN NEW, STATE-OF-THE-ART CENTER FOR SCIENCE AND INNOVATION AT U.S. GLOBAL HEADQUARTERS
AMGEN INVESTING MORE THAN HALF A BILLION DOLLARS IN NEW, STATE-​OF-THE-ART CENTER FOR SCIENCE AND INNOVATION AT U.S. GLOBAL HEADQUARTERS PR ...
29.08.25 - PR Newswire
AMGEN TO PRESENT AT THE 2025 WELLS FARGO HEALTHCARE CONFERENCE
AMGEN TO PRESENT AT THE 2025 WELLS FARGO HEALTHCARE CONFERENCE PR Newswire
06.08.25 - PR Newswire
Clinical Progress in Rare Disease Signals Long-Term Revenue Potential for Innovators
Clinical Progress in Rare Disease Signals Long-Term Revenue Potential for Innovators PR Newswire
06.08.25 - PR Newswire
Clinical Progress in Rare Disease Signals Long-Term Revenue Potential for Innovators
Clinical Progress in Rare Disease Signals Long-Term Revenue Potential for Innovators PR Newswire
05.08.25 - wallstreetONLINE Redaktion
Steigende Ausschüttungen: Einkommensinvestoren aufgepasst! 3 Aktien mit stark wachsenden Dividenden
Das Analysehaus Morningstar hat für den August 3 Aktien mit attraktiver Dividendenrendite herausgepickt. Diese bestechen durch Konstanz und wachsende Ausschüttungen. ...
05.08.25 - PR Newswire
AMGEN REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS
AMGEN REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS PR Newswire
01.08.25 - PR Newswire
AMGEN ANNOUNCES 2025 THIRD QUARTER DIVIDEND
AMGEN ANNOUNCES 2025 THIRD QUARTER DIVIDEND PR Newswire
31.07.25 - PR Newswire
AMGEN ANNOUNCES WEBCAST OF 2025 SECOND QUARTER FINANCIAL RESULTS
AMGEN ANNOUNCES WEBCAST OF 2025 SECOND QUARTER FINANCIAL RESULTS PR Newswire

Newssuche

Videos

newspaper
22.01.26 -33,33%
Trading Insights vom 22.01.26
Preisschock bei Erdgas! Was sind die Gründe, wie geht man damit um? Gold auf neuem Allzeithoch: wie ... Mehr »